Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrophosphoric Acid SCHEMBL28750281 | 0.78 | FDPS (0.77) | FDPSBLMTDP1LMNABTN3A1 | |
| Pyrophosphoric Acid SCHEMBL28456752 | 0.75 | FDPS (0.83) | FDPSBLMTDP1BTN3A1CA2 | |
| Pyrophosphoric Acid SCHEMBL3910021 | 0.75 | FDPS (0.83) | FDPSBLMTDP1BTN3A1CA2 | |
| Pyrophosphoric Acid SCHEMBL27780224 | 0.75 | FDPS (0.83) | FDPSBLMTDP1BTN3A1CA2 | |
| Pyrophosphoric Acid SCHEMBL548182 | 0.75 | FDPS (0.83) | FDPSBLMTDP1BTN3A1CA2 | |
| Pyrophosphoric Acid SCHEMBL29634664 | 0.74 | — | — | |
| Pyrophosphoric Acid SCHEMBL3654 | 0.74 | — | — | |
| Pyrophosphoric Acid SCHEMBL292348 | 0.74 | FDPS (1.00) | FDPSBLMTDP1BTN3A1CA2 | |
| Pyrophosphoric Acid SCHEMBL8851914 | 0.74 | FDPS (1.00) | FDPSBLMTDP1BTN3A1CA2 | |
| Pyrophosphoric Acid SCHEMBL23537746 | 0.71 | FDPS (0.91) | FDPSBLMTDP1BTN3A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9035041-B2 | Process for triphosphate oligonucleotide synthesis | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20120220761-A1 | PROCESS FOR TRIPHOSPHATE OLIGONUCLEOTIDE SYNTHESIS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20110282044-A1 | PROCESS FOR SYNTHESIZING OLIGONUCLEOTIDE PHOSPHATE DERIVATIVES | ALNYLAM PHARMACEUTICALS (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220761-A1 | PROCESS FOR TRIPHOSPHATE OLIGONUCLEOTIDE SYNTHESIS | DUT, DTYMK, ITPA | FDPS 43/4885BLM 1145/4885TDP1 337/4885 |
| US-20110282044-A1 | PROCESS FOR SYNTHESIZING OLIGONUCLEOTIDE PHOSPHATE DERIVATIVES | PPA1, TYMP, DCTPP1 | FDPS 44/4885BLM 1471/4885TDP1 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.